Biohit Oyj B 

€2.14
4
+€0+0% Friday 14:59

統計

當日最高
2.14
當日最低
2.1
52週最高
2.47
52週最低
1.8
成交量
3,942
平均成交量
12,027
市值
32.47M
市盈率
19.36
股息收益率
-
股息
-

即將到來

股息

0%股息收益率
10年增長
N/A
5年增長率
N/A
3年增長率
N/A
1年增長率
N/A

收益

7Aug預期
Q4 2015
Q4 2017
Q1 2018
Q4 2018
Q4 2023
Q1 2024
Q2 2024
-0.1
-0.04
0.02
0.09
預期每股收益
0.088252040376
實際每股收益
0.0811006833708648

人們還關注

此列表基於在 Stock Events 上關注 BIOBV.HE 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

關於

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company's diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist clinicians and general practitioner; Biohit Active B12, a test for measuring the levels of active vitamin B12; BIOHIT Total 25OH Vitamin D, a test for determination of vitamin D status; and Biohit Calprotectin test for measuring human calprotectin. It also offers GastroPanel quick test NT, a quantitative immunochromatographic test for the detection of Helicobacter pylori (H. Pylori) and atrophic gastritis; BIOHIT Celiac Quick test for diagnosis of celiac disease; Biohit ColonView Quick test, a test for detection of fecal occult blood; Biohit Helicobacter Pylori UFT300 and Helicobacter Pylori Quick test methods to detect H. pylori infection; and Lactose Intolerance quick test to support the diagnosis of lactose intolerance in a duodenal biopsy specimen. In addition, the company provides acetaldehyde-binding products, such as Acetium capsules that are intended for persons with a low-acid or anacidic stomach; and Acetium lozenge, which helps in quitting smoking; and monoclonal antibodies for use in the areas of cellular pathology, neurobiology, oncology, and human gastric biomarkers research. The company was incorporated in 1988 and is headquartered in Helsinki, Finland.
Show more...
首席執行官
Prof. Osmo Antero Suovaniemi M.D., Ph.D.
員工
47
國家
FI

上市公司